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Humoral and cellular immune responsesWe evaluated the potential of a liposomal antigen delivery system (ADS) containing Candida albicans cell
wall surface proteins (CWSP) in mediating protection against systemic candidiasis. Treatment of bone-
marrow-derived dendritic cells with CWSP-loaded dioctadecyldimethylammonium bromide:monoolein
(DODAB:MO) liposomes enhanced and prolonged their activation comparatively to free antigen, indicat-
ing that liposome-entrapped CWSP were released more sustainable. Therefore, we immunized mice with
CWSP either in a free form or loaded into two different DODAB:MO liposome formulations, respectively
designated as ADS1 and ADS2, prior to intravenous C. albicans infection. Immunization with ADS1, but not
with ADS2, conferred significant protection to infected mice, comparatively to immunization with CWSP
or empty liposomes as control. ADS1-immunized mice presented significantly higher serum levels of C.
albicans-specific antibodies that enhanced phagocytosis of this fungus. In these mice, a mixed cytokine
production profile was observed encompassing IFN-c, IL-4, IL-17A and IL-10. Nevertheless, only produc-
tion of IL-4, IL-17 and IL-10 was higher than in controls. In this study we demonstrated that DODAB:MO
liposomes enhance the immunogenicity of C. albicans antigens and host protection in a murine model of
systemic candidiasis. Therefore, this liposomal adjuvant could be a promising candidate to assess in
vaccination against this pathogenic fungus.
Statement of Significance
This work describes the immunomodulation capacity of the previously validated antigen delivery system
(ADS) composed by dioctadecyldimethylammonium bromide (DODAB) and monoolein (MO) lipids incor-
porating the cell wall surface proteins (CWSP) from C. albicans. Here, we not only present the ability of
this system in facilitating antigen uptake by DCs in vitro, but also that this system induces higher levels
of pro-inflammatory cytokines and opsonizing specific IgG antibodies in serum of mice immunized
subcutaneously. We show that the ADS are efficient nanocarrier and modulate the immune response
against intravenous C. albicans infection favoring mouse protection. In sum, we show that the incorpora-
tion of C. albicans antigens in DODAB:MO nanocarries are a promising vaccine strategy against C. albicans
fungal infection.
 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.1. Introduction
Vaccines are routinely used to protect against microbial patho-
gens. They usually contain antigens as surrogates of the disease-
causing microorganism or a product of it. Antigens may include
weakened or inactivated forms of the target pathogen, or subunits
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less, the use of attenuated pathogens raises several safety issues
due to possible reversion of the phenotype or residual virulence.
These safety problems may be circumvented by using subunit vac-
cines. In such case, univalent subunit vaccines may have their
effectiveness limited due to antigen variations in the target patho-
gens. The use of complex antigen extracts, instead of single mole-
cules, in the immunogenic preparations may be a way to overcome
this issue [2]. Yet, the effective implementation of subunit vaccines
is frequently impaired by insufficient immunogenicity when
administered without adjuvant [3,4]. Therefore, selecting an
appropriate adjuvant or delivery system is as important as select-
ing antigen candidates.
Formulating protein antigens into nanoparticles has emerged as
one of the most promising strategies to enhance the immune
response to vaccine antigens [5–9]. Cationic liposomes are inter-
esting adjuvants that also serve as carriers for the targeted delivery
of antigens to immune cells. These liposomes tightly bind nega-
tively charged antigens, which may render soluble antigens into
a particulate form thereby increasing their in vivo half-life [7,9].
In fact, cationic liposomes were used as adjuvants in several stud-
ies, enhancing cell mediated or humoral immunity, as well as
delivery systems for drugs, DNA or peptides [5,6,10]. Major limita-
tions behind the fact that as yet no adjuvant based on liposomes
has been registered for human use seem to be their stability, man-
ufacturing and quality assurance problems [11]. However, these
limitations may be overcome by tuning physicochemical proper-
ties like size, charge and hydrophobicity [12–14]. Recently, a direct
comparative study showed that cationic liposomes were most effi-
cient for the induction of effector antigen-specific T cells in vivo,
than poly-(lactic-coglycolic-acid) (PLGA) nanoparticles or the clin-
ically used adjuvants Montanide ISA-51 and SWE, a squalene oil-
in-water emulsion [13].
Cationic liposomes composed by surfactant dioctade-
cyldimethylammonium bromide (DODAB) have been used as carri-
ers in drug delivery studies [8,15] as well as adjuvants in
vaccination strategies, displaying higher colloidal stability than
aluminum hydroxide and better efficacy in inducing cellular
immune responses [16–18]. The main advantage of DODAB as an
adjuvant is that it requires a lipid concentration lower than the
concentrations traditionally used in liposomal formulations
[19,20]. However, these preparations can be physically unstable
and therefore the incorporation of different neutral molecules,
such as cholesterol, 1-monopalmitoyl glycerol and trehalose
6,60-dibehenate have shown to improve the stability without
undermining their adjuvanticity [21]. In previous studies we have
demonstrated that monoolein (MO), when incorporated as helper
lipid with DODAB, could act as a stabilizer, conferring fluidity to
the DODAB nanoparticle liposomes by favoring lipid chain mobility
[22]. We have successfully used DODAB:MO as a mammalian cell
transfection system and as a nanocarrier for in vitro gene silencing
[15,23]. In particular, we demonstrated that liposomes formed by
DODAB and MO at DODAB:MO (1:2) molar ratio, assembled mainly
as positively spherical bilamellar vesicles with some internal struc-
tures [24]. In this way, in a recent report, we explored this formu-
lation, DODAB:MO (1:2), and described the development of two
liposomal nanoparticle antigen delivery systems (ADS), ADS1 and
ADS2, loaded with Candida albicans cell wall surface proteins
(CWSP) as antigens. These ADS assembled as stable negatively
charged spherical nanoparticles with an average particle size of
approximately 280 nm, indicating that the CWSP readily associ-
ated with the liposomes [25]. This efficient adsorption onto the
liposomes and their size, mimicking that of natural pathogens,
induced a strong, humoral and cell-mediated immunity when
compared with free CWSP [26]. C. albicans is an opportunistic
human pathogen and is by far the most common cause of fungalinvasive infections [25]. Despite the availability of new antifungal
agents, candidemia is the fourth most common bloodstream infec-
tion in hospitalized patients both in the United States and in many
European countries [27–29].
Consequently, antifungal vaccines are currently considered one
of the most appealing and cost effective strategies against Candida
infections [27,30–32]. As far as we know, only two vaccines against
C. albicans infections have completed Phase I clinical trials, the
adhesin-like substance 3 (Als3) with aluminum hydroxide as the
adjuvant (NDV-3; NovaDigm Therapeutics) [33], and secreted
aspartic protease 2 (Sap2) embedded in a virosomal for adjuvantic-
ity (PEV-7; Pevion Biotech) [34].
In this work, we assessed the effectiveness of the designed
DODAB:MO liposomal nanoparticle associated with a C. albicans
CWSP preparation in inducing protection in a mouse model of sys-
temic candidiasis established by the hematogenous route. Our
results showed that these liposomal systems induced strong
opsonizing antibody responses and a cell-mediated immune
response that allowed a significant protection of infected mice.2. Material and methods
2.1. Materials
Dioctadecyldimethylammonium bromide (DODAB) was pur-
chased from Tokyo Kasei (Japan). 1-monooleoyl-rac-glycerol
(MO), Hanks’ balanced salt solution (HBSS), glutaraldehyde, pro-
pidium iodide (PI) and DTT were supplied by Sigma–Aldrich (St.
Louis, MO, USA). Tris–HCl Buffer was provided by Invitrogen/
Molecular Probes (Eugene, OR, USA) and ethanol (high spectral
purity) was purchased from Uvasol (Leicester, United Kingdom).
Dulbecco’s Modified Eagle’s Medium (DMEM) was supplemented
with 2 mM L-glutamine, (all from Sigma-Aldrich) and 10% heat-
inactivated fetal bovine serum (FBS) provided by Lonz (Romania);
HEPES-Buffer solution pH 7.5 was provided by VWR International
(Radnor, PA, USA) and 1 mM sodium pyruvate by Merck (Frankfurt,
Germany). Sytox Green was purchased from Thermo Fisher Scien-
tific (Massachusetts, MA, USA) and propidium iodide (PI) was
obtained form Sigma-Aldrich.
2.2. Culture conditions of C. albicans strains
C. albicans strain SC5314 was used for CWSP extraction while C.
albicans 124A clinical isolate [35] was used for infection experi-
ments. All strains were maintained as frozen stocks in 30% glycerol
at 80 C. When needed, yeasts were obtained from a 2 day YPD
agar plate (2% D-glucose, 1% Difco yeast extract, 2% peptone and
2% agar) (w/v) incubated at 30 C.
2.3. Extraction of yeast CWSP
All procedures used for CWSP extraction were performed in a
sterile environment and using apyrogenic solutions. CWSP were
released from intact yeast cells by DTT treatment as described pre-
viously [26]. The concentrated proteins obtained were stored at
80 C in aliquots of 100 lg/ml.
2.4. Preparation and characterization of CWSP-loaded liposomes
DODAB:MO based liposomes were prepared using the lipid-film
hydration method [36]. Briefly, DODAB and MO, at a DODAB molar
fraction (vDODAB) of 0.33, were dissolved in ethanol and mixed in
a round-bottom flask. The solvent was removed by rotary evapora-
tion, at a temperature 10 C above the main phase transition of
DODAB (Tm  44 C), and liposomes formed after hydration of
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was then placed in a bath sonicator during 2 min.
Two liposomal stock dispersions were prepared, stock 1, used
for ADS1, at a total lipid concentration of 1774 lg/ml and stock
2, used for ADS2, at a total lipid concentration of 266 lg/ml. For
the ADSs assembling, equal volumes of CWSP were added to the
respective stock dispersions post lipid-film hydration. For both
ADS the final concentration of CWSP was 50 lg/ml. For ADS1, the
final total lipid concentration was 888 lg/ml and for ADS2 was
133 lg/ml (Table 1). The empty liposomes (EL) were always used
at a final total lipid concentration of 888 lg/ml. These formulations
were then incubated for 1 h, at 55 C, to ensure CWSP adsorption
followed by a brief sonication step in a water-bath sonicator.
2.5. Quantification of protein retention
ADS1, ADS2 and empty liposomes were prepared as described
in Section 2.4. Protein retention was evaluated at different time
points, 0, 3, 24, 48 and 72 h after preparation. The prepared formu-
lations were pelleted by ultracentrifugation (100,000g for 1 h), the
pellet submitted to TCA protein precipitation (Thermo Scientific
Pierce), and the proteins quantified with the BCA Protein Assay
Kit (Thermo Scientific Pierce), according to the manufacturer’s
instructions. Empty liposomes were used as a negative control in
order to exclude lipid interference in the protein quantification
method.
2.6. Stimulation of bone marrow-derived DC (BMDC)
Bone marrow cells were collected from femurs and tibias of
female BALB/c mice by flushing with cold RPMI 1640 (Sigma).
BMDC were differentiated as described by Cerca et al. [37]. Briefly,
cells (1  106/mL) were cultured in 6-well plates in RPMI supple-
mented with 15% (v/v) J558-cell supernatant, 10% FBS penicillin
(100 U.I./mL)-streptomycin (100 lg/ml) (Sigma), and L-glutamine
(2 mM) (Sigma) and incubated at 37 C and 5% CO2. Half of the
medium was renewed every two days. At day 8, BMDCs were
detached and distributed in 96-well round bottom plates adjusted
at a concentration of 2  105 cells/well in supplemented RPMI
medium. Differentiation of bone marrow precursors into BMDC
was confirmed by flow cytometry assessing surface expression of
CD11c, CD80, CD86 and MHC class II (Fig. S1). Immediately after
being seeded, cells were stimulated with 10 ll of CWPS (0.5 lg),
ADS1 (0.5 lg of CWSP loaded in 8.8 lg of total lipid), ADS2
(0.5 lg of CWSP loaded in 1.33 lg of total lipid) or EL (8.8 lg of
total lipid) in a final volume of 200 ll. LPS (1 lg/ml) (Sigma) and
un-stimulated cells were used as positive and negative controls
of activation, respectively. After 6 or 24 h, the culture supernatants
were removed and stored at -80 C. For the assessment of cell sur-
face markers, after stimulation, the BMDC were collected from the
culture plates, washed twice in Hanks’s Balanced Salt SolutionTable 1
Composition, mean size and f-potential of ADS. DODAB:MO liposomes were mixed
with CWSP for 1 h to prepare ADS1 and ADS2. Mean size and f-potential were
measured by dynamic light scattering on a ZetaSizer NanoZS. PDI: polydispersity
index.




888 133 – 888
CWSP added
(lg/ml)
50 50 50 –
Mean size (nm) 223 ± 37 255 ± 46 88.7 ± 5.1 176.8 ± 23
PDI 0.19 ± 0.015 0.25 ± 0.017 0.63 ± 0.01 0.24 ± 0.08
f-potential (mv) 18.3 ± 1.5 21.8 ± 1.4 14 ± 0.7 54.6 ± 3.2(Sigma) and incubated with specific monoclonal antibodies
(mAb). The following mAbs, along with their respective isotype
controls were used (at previously determined optimal dilutions
[38] for immunofluorescence cytometry: fluorescein isothio-
cyanate (FITC) hamster anti-mouse CD11c (HL3), phycoerythrin
(PE) anti-mouse CD80 (B7-1) (16-10A1); phycoerythrin-cyanine 7
(PE-Cy7) anti-mouse CD86 (B7-2) (GL1); peridinin-chlorophyll
protein (PerCp) anti-mouse I-Ad/I-Ed (clone 2G9); all from BD Bio-
sciences Pharmingen, San Diego, CA. The analyzed cell samples
were always pre-incubated with anti-FccR mAb before the anti-
body incubation to prevent non-specific antibody binding. All cyto-
metric measurements were performed in an EPICS XL flow
cytometer using the EXPO32ADC software (Beckman Coulter).
The collected data files were analyzed using FLOWJO X 10.0.7r2
software.
The concentrations of IL-23, IL-12 and TNF-a in cell culture
supernatants were quantified with the respective Mouse
enzyme-linked immunosorbent assay (ELISA) Ready-Set-Go kit
(eBioscience, San Diego, CA) while IL-10 was quantified using the
Mouse IL-10 DuoSet ELISA development system (R&D Systems,
Minneapolis, MN); according to the manufacturer’s instructions.
2.7. Cellular delivery of proteins via ADS
Confocal microscopy was performed as described before [26].
Briefly, macrophages (RAW 264.7 cell line) were plated in 6-well
chamber plates (Ibidi) 3  105 cells/well and left to adhere over-
night at 37 C in a humidified atmosphere of 5% CO2. Prior to
ADS preparation, Rhodamine (Rho) DHPE (at a molar ratio of
1:200) was incorporated into DODAB:MO liposomes during the
preparation phase, prior to solvent removal by rotary evaporation.
Before incubation with Rho-DHPE labeled ADS, macrophages were
labeled with Wheat Germ Agglutinin Alexa Fluor 633 Conjugated.
Labeled macrophages were then incubated with labeled ADS, the
microscopy chamber plate was placed in the integrated chamber
(37 C, 5% CO2) of LSM 780 Carl Zeiss and a mid-point cell thickness
view images and z-stack images were obtained after 60 min.
Images were analyzed using ZEN 2012 lite software (ZEISS).
2.8. Immunization procedures
Female BALB/c mice, 8–10 weeks old, were purchased from
Charles River (Barcelona, Spain) and kept under specific-
pathogen-free conditions at the Animal Facility of the Instituto
de Ciências Biomédicas Abel Salazar, Porto, Portugal. All proce-
dures involving mice were performed according to the European
Convention for the Protection of Vertebrate Animals used for
Experimental and other Scientific Purposes (ETS 123), the
86/609/EEC directive and Portuguese rules (DL 129/92). Twenty
BALB/c mice per group, were injected subcutaneously three times
with a 2-week intervening period, with 200 ll of one of the follow-
ing preparations: CWSP alone (50 lg/ml); DODAB:MO EL (888 lg/
ml), ADS1 (50:888 lg/ml; CWSP:Lipid) or ADS2 (50:133 lg/ml;
CWSP:Lipid). Additionally, a group of six mice was injected with
HEPES-Buffer (vehicle), following the same immunization proce-
dure. The schematic representation of the immunization protocol
is shown in Fig. S2. Blood samples were collected in the sub-
mandibular vein on day 35 of the immunization protocol to obtain
serum samples to confirm immunization efficiency.
2.9. C. albicans hematogenously disseminated infections
BALB/c mice were infected intravenously (i.v.) with 1  105 C.
albicans yeast-form cells, according to the schedule presented in
Fig. S2. C. albicans inoculum for infection was grown in a shaking
incubator for 14 h at 30 C in Winge medium (0.2% glucose, 0.3%
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ile, apyrogenic phosphate-buffered saline (PBS), counted in a
hemocytometer, and resuspended at the appropriate concentra-
tions. Inocula were always confirmed by colony forming units
(CFU) counts on YPD agar plates at 37 C for up to 48 h. In order
to assess survival, eight mice of each of the four immunized groups,
and the mouse group treated with the vehicle alone, were infected,
weighted and monitored twice daily to evaluate the progress of
hematological disseminated candidiasis. Mice attaining estab-
lished human end points were humanely sacrificed using isoflu-
rane anesthesia followed by cervical dislocation. Their deaths
were recorded as occurring on the following day. To determine
immunological parameters, eight mice of each immunized group
were also infected with 1  105 C. albicans cells and sacrificed three
and seven days after infection to collect blood and spleens.
2.10. Intracytoplasmic cytokine quantification
At days 49 (before infection), 52 and 56 (three and seven days
post-infection, respectively) four immunized mice per group were
sacrificed and the spleens were aseptically removed, homogenized
in Hanks’ balanced salt solution (Sigma) and red blood cells lysed
with 0.15 M ammonium chloride. The remaining cells were
counted and plated in round-bottom 96-well plates (Nunc,
1  106 cells) in RPMI-1640 compete medium [RPMI-1640 (Sigma)
supplemented with 10% FBS, HEPES (10 mM), penicillin (200 IU/
ml), streptomycin (200 g/ml) (all from Sigma) and 2-
mercaptoethanol (0.1 mM) (Merk)]. Cells were incubated in a
humidified atmosphere with 5% CO2 at 37 for 5 h under stimula-
tion with 20 ng/ml PMA (Sigma), 200 ng/ml ionomycin (Merk)
and 10 ng/ml brefeldin A (Epicentre Biotechologies, Madison, WI,
USA). Then, cells were recovered and non-specific antibody binding
was prevented by the pre-incubation with anti-FccR mAb followed
by incubation with anti-CD4 peridinin-chlorophyll protein-
cychrome 5.5 (PerCP-Cy5.5)-conjugated (clone RM4-5). Following
extracellular CD4 staining cells were washed, fixed in 2% formalde-
hyde, washed again and permeabilized with 0.05% saponin (Sigma)
in PBS solution. Intracytoplasmic staining was carried out with
anti-interferon-c (IFN-c) FITC-conjugated (clone XMG1.2) (Biole-
gend) and anti-IL-10 PE-conjugated (clone JES5-16E3) (BD Bio-
sciences) or with anti-IL-4 PE-conjugated (clone BVD4-1D11) (BD
Biosciences) and anti-IL-17A FITC conjugated (clone TC11-
18H10.1) (Biolegend). Antibody-labeled cells were analyzed in an
EPICS XL flow cytometer using the EXPO32ADC software (Beckman
Coulter). At least 150 000 events were acquired per sample. The
collected data files were analyzed using FLOWJO X 10.0.7r2
software.
2.11. In vitro antigen-recall stimulation assay and cytokine
quantification
To assess cytokine production by CWSP-stimulated spleen cells,
5 ml aliquots of cell suspensions prepared as described above for
intra-cytoplasmic staining, were layered onto 2.5 ml of a
polysucrose-sodium ditrizoate solution (Histopaque 1083, Sigma)
and centrifuged at 800g for 20 min at room temperature. Mononu-
clear cells collected from the medium–Histopaque interface were
collected, washed, suspended in RPMI-1640 complete medium,
plated (5  105/well) in round-bottom 96-well plates, and stimu-
lated with CWSP (final concentration of 20 lg/ml) for 3 days at
37 and 5% CO2. The concentrations of IFN-c, IL-4 and IL-17A in cell
culture supernatants were quantified with the respective Mouse
ELISA Ready-Set-Go kit (eBioscience, San Diego, CA) while IL-10
was quantified using the Mouse IL-10 DuoSet ELISA development
system (R&D Systems, Minneapolis, MN) according to the manu-
facturer’s instructions.2.12. Quantification of CWSP-specific antibodies
Specific anti-CWSP immunoglobulins in the collected serum
were quantified by ELISA according to Ferreirinha et al. [39].
Briefly, polystyrene microtitre plates (Nunc, Roskilde, Denmark)
were coated with 5 lg/ml CWSP and incubated overnight at 4 C.
Wells were then saturated for 1 h at room temperature with 1%
BSA in Tris-saline Tween 20 (TST) (w/v) and serial dilutions of
the serum samples were plated and incubated for 2 h at room tem-
perature. After washing, alkaline phosphatase-coupled monoclonal
goat anti-mouse IgG1 and IgG2a (Southern Biotechnology Associ-
ates, Birmingham, AL) were added and incubated for 1 h at room
temperature. After washing, the specifically bound antibodies were
detected by adding the p-nitrophenyl phosphate (Sigma) substrate
solution and on development the reaction was stopped by the
addition of 0.1 M EDTA, pH 8 solution. The absorbance was mea-
sured at 405 nm, subtracting for each well the value of the absor-
bance at 570 nm. The antibody titers were expressed as the
reciprocal of the highest dilution with an absorbance 2 fold higher
than the value of the control (no serum added).
2.13. Phagocytosis of opsonized C. albicans cells
Phagocytosis was assessed by flow cytometry following a previ-
ously described method [40]. Briefly, fixed C. albicans cells were
labeled with Sytox Green and incubated in Dulbecco’s modified
Eagle medium (DMEM) during 30 min at 37 C with 20% mouse
serum collected from mice immunized thrice with CWSP, ADS1,
ADS2 or EL. Serum from four independent mice was used, each
one in triplicate. Then, cells were washed twice with PBS and
resuspended in DMEM without serum. RAW 264.7 macrophages
were incubated with labeled yeast suspensions at a multiplicity
of infection (MOI) of 1 macrophage per 5 yeast cells, for 30 min,
at 37 C and 5% CO2. After incubation, plates were kept on ice to
stop phagocytosis, and wells rinsed twice with PBS to remove
unbound yeasts. Macrophages and associated yeasts were then
incubated with PI at a final concentration of 6 lg/ml, for 5 min at
RT. The percentage of macrophages with internalized cells (Sytox+
PI and Sytox+PI+), as well as the percentage of macrophages with
adherent cells (SytoxPI+), was determined as previously described
[40]. Phagocytosis was confirmed by confocal microscopy (Leica
SP2 AOBS SE) and images were analyzed using Fiji-ImageJ software
2.00 (NIH-USA).
2.14. Statistical analyses
Data were analyzed using analysis of variance (ANOVA) fol-
lowed by Bonferroni post-test to compare the mean values of the
different groups, using GraphPad Prism 5 software (GraphPad Soft-
ware, Inc., La Jolla, CA, USA). Unless otherwise stated, results
shown are from at least three independent experiments with three
replicates. Differences were considered significant when the P
value was lower than 0.05.3. Results
3.1. Characterization of ADS, quantification of protein retention and
delivery
ADS used here were prepared using preformed DODAB:MO
liposomes loaded with CWSP (50 lg/ml) as previously described
[26]. ADS1 presented a size around 223 ± 37 nm with a polydisper-
sity index (PDI) of 0.19 ± 0.015, while ADS2 had a similar size,
255 ± 46 nm, but were more polydisperse, 0.25 ± 0.017 (Table 1).
These ADS were negatively charged, with ADS1 presenting a
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21.8 ± 1.5 mV, while DODAB:MO EL exhibited a f-potential value
of 54.6 ± 3.2 mV, showing that antigenic proteins (CWSP) are sur-
face adsorbed to liposomes. Owing to the complexity of Candida
cell wall antigens and their surface localization, we thus focused
on the stability over time of the proteins associated with the lipo-
somes when stored at 4 C. Immediately after formulation assem-
bling (time 0), ADS1 presented 91 ± 12% of the proteins adsorbed
while ADS2 showed only 25 ± 12% (Fig. 1). Although by 48 h
approximately 12.6% of CWSP were released from the surface of
ADS1 liposomes and 17.1% from the surface of ADS2, no significant
changes were observed over 72 h after preparation. Thus, in this
study, both ADS1 and ADS2 were used within 48 h after prepara-
tion to ensure the% of CWSP absorbed. In this way, the effective
concentration calculated taking into consideration the 50 lg/ml
of total protein initially added ranged from 45.5 ± 6–39.2 ± 3 lg/
ml (91 ± 12–78.4 ± 5 of CWSP absorption) for ADS1 and from
12.5 ± 6–10.3 ± 1 lg/ml (25 ± 12–20.7 ± 3% of CWSP absorption)
for ADS2. These results highlighted the fact that the interac-
tions between DODAB:MO liposomes and CWSP proteins are
strong and protein adsorption on to ADS1 or ADS2 is stable, at least
over a range of 72 h after liposomes preparation and storage at
4 C.
In a previous study we have shown that ADS1 and ADS2 were
non-toxic to J774A.1 macrophages and were avidly internalized
by these cells [26]. In this study we confirmed by confocal micro-
scopy that after 60 min of incubation ADS1 also effectively deliv-
ered CWSP into RAW 264.7 macrophages (Fig. 2). The results
obtained with these different cell lines, indicate that these ADS
are able to efficiently deliver antigens into macrophages that
may trigger T and B cells in vivo.
3.2. Immunostimulatory effect of ADS on dendritic cells
The activation of antigen presenting cells (APC), such as den-
dritic cells, is one of the fundamental steps in inducing an effective
in vivo immune response [14]. Therefore, we evaluated the ability
of the formulations to activate BMDC in vitro by measuring surface
expression of T cell co-stimulatory (CD80 and CD86) and MHC
class II molecules, and by quantifying the production of pro-
inflammatory cytokines TNF-a, IL-12 and IL-23 and anti-
inflammatory cytokine IL-10 in the culture supernatants.
Fig. 3a shows that upon 6 h stimulation with CWSP, ADS1 and
ADS2, BMDC already presented a significantly higher expressionFig. 1. Percentage of CWSP retention in ADS1 and ADS2 over time. ADS were
prepared, stored at 4 C, and retention of CWSP antigen was monitored during 72 h
after preparation. Each bar represents mean + SD of the percentage retention of
initial antigen added (50 lg/ml for both ADSs). Data shown are representative
results of two independent experiments (N = 3 per experiment).of all the surface activation markers analyzed in comparison with
unstimulated or EL stimulated cells. At this time point, no higher
expression of the assessed BMDC cell surface markers was induced
by any ADS, as compared to CWSP. Actually, ADS1-induced CD80
expression was lower than the one induced by CSWP. Contrast-
ingly however, after 24 h incubation a markedly higher surface
CD80, CD86 and MHC II expression was observed in the BMDC
stimulated with ADS1 as compared to that induced by free CWSP
(Fig. 3a). In contrast to ADS1, ADS2 did not promote an enhanced
expression of those dendritic cell surface markers, comparatively
to CWSP.
BMDC stimulated for 6 h with either CWSP or ADS2 produced
similar levels of TNF-a and IL-12 as those stimulated with LPS, a
strong activator of the innate immune system and a potent inducer
of inflammation [41]. CWSP and ADS2 stimulated cells also pro-
duced significantly higher amounts of IL-23 and IL-10 when com-
pared with stimulation by ADS1 or EL (Fig. 3b). After 24 h
stimulation, the levels of TNF-a, IL-12 as well as of IL-10 were
maintained or enhanced in the cell culture supernatants of
CWSP- or ADS2-stimulated BMDC, while those of IL-23 were lower,
as compared to the respective ones detected at 6 h. Contrastingly,
stimulation with ADS1 led to intermediate levels of all cytokines,
ranging between the ones detected when using CWSP or ADS2,
and EL (Fig. 3b).
These results suggested that although both ADS1 and ADS2 acti-
vated BMDC, ADS2 and free CWSP appeared to be the most inflam-
matory stimuli. While ADS1 could stimulate BMDC, as assessed by
significantly enhanced expression of surface co-stimulatory and
MHC II proteins, the induced production of inflammatory cytokines
as well as of IL-10 were significantly lower than the ones observed
for ADS2 and CWSP.3.3. Production of antigen-specific antibodies in vivo
Having determined that ADS1 and ADS2 stimulated BMDC, we
next immunized BALB/c mice with these formulations. The serum
titers of CWSP-specific IgG1 and IgG2a antibodies were determined
in mice immunized with free CWSP, ADS1 and ADS2 or sham-
immunized with EL as controls. As previously reported, mice
immunized with free CWSP or ADS raised antigen-specific IgG anti-
bodies that were significantly higher in the ADS1 immunized
group, as compared to the other assessed groups (Fig. 4a). Mice
immunized with ADS2 or free CWSP presented similar levels of
anti-CWSP IgG1 and IgG2a antibodies. The efficacy of serum from
immunized mice in enhancing the phagocytosis of C. albicans cells
was then tested in vitro and analyzed by flow cytometry using a
previous described method that enables the discrimination of
yeast cells that are internalized from yeast cells that are only
adhered to phagocytes (fig. 4c) [40]. As shown in Fig. 4b, C. albicans
cells pre-treated with serum from mice immunized with ADS1 and
ADS2 were significantly more internalized by macrophages than
non-opsonized yeast cells or cells opsonized with serum frommice
sham-immunized with EL or immunized with CWSP alone. This
indicates that the increased percentage of C. albicans yeasts inter-
nalized by macrophages was due to CWSP-specific IgG yeast
opsonization. Although serum from CWSP-immunized mice con-
tained CWSP-specific IgG, no differences in the percentage of inter-
nalized yeast were observed for yeast cells treated with this serum
in comparison with cells treated with serum frommice immunized
with EL. This result might be a consequence of low CWSP-specific
IgG titles detected in serum of mice immunized with free antigen.
According to all these results, mice immunized with ADS presented
a significant increase in serum CWSP-specific antibody titers
before infection that markedly enhanced ex vivo phagocytosis of
C. albicans yeast cells.
Fig. 2. Cellular uptake of empty liposomes and ADS1 after 1 h incubation. The membranes of macrophage cells were labeled with wheat germ agglutinin Alexa Fluor 633
conjugate followed by incubation with rhodamine-labeled liposomes. Representation of a mid-point thickness view (X68, Y44, Z24). (z). Z-axis rotations of a single transverse
slice through two sections of the cell: view in the x-0-z plane (x) and view in the y-0-z plane (y). The scale bar represents 10 nm.
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albicans infection
In order to evaluate the protective effect of ADS1 and ADS2
immunization against systemic candidiasis, s.c. vaccinated and
control mice were challenged at day 49 with a clinical C. albicans
isolate obtained from a patient with systemic infection (strain
124A [35]). The immunization protocol is schematized in Fig. S2
(supplementary data). Mice were weighted and visually monitored
for signs of disease over 50 days. Mice sham-immunized with EL
were the first attaining established humane endpoints, by day 8
upon infection and were closely followed by mice of the CWSP
and ADS2 immunized groups. In the ADS1 immunized group, only
by day 15 the first mouse death was recorded (Fig. 5). Moreover,
only the ADS1 immunized group presented a significantly
extended survival as compared to any of the other experimental
groups. By the end of the experimental period, 62.5% of the mice
immunized with ADS1 survived infection as compared to 12.5%
in the EL treated group and 100% mortality in the CWSP and
ADS2 immunized groups. These results show that ADS1, but not
the other immunogenic preparations, conferred protection against
C. albicans challenge. Moreover, as the C. albicans strain used to iso-
late CWSP antigens was different from the one used to infect the
immunized mice it may indicate that achieved protection could
be strain-independent.
3.5. Splenocytes stimulation and intracellular cytokine quantification
Cell-mediated immunity is essential for the control of C. albi-
cans and Th1- and Th17-type cytokines are critical for coordinating
protective immunity against the fungus [42]. Thus, to determine
whether the immunization with either ADS could induce a partic-
ular type of T cell polarization, the expression of IFN-c, IL-4, IL-10
and IL-17 was assessed by flow cytometry in splenic CD4+ T cells
collected from mice of the different assessed groups (Fig. 6). IFN-
c and IL-17 are main effectors in the protective immune response
to C. albicans [43]. The detected proportions of IL-17+CD4+ T
splenocytes were significantly and markedly higher in the ADS1-
immunized mice, as particularly evident in 3-day infected mice.Contrastingly, the frequency of splenic CD4+ T cells producing
IFN-c was not majorly altered among groups upon infection. Nev-
ertheless, significantly lower frequency of IFN-c+CD4+ cells was
detected in the ADS1-immunized mice as compared with the fre-
quency found for CWSP-immunized mice. Immunization with
ADS1 or ADS2 also increased the proportions of splenic IL-4+ and
IL-10+ CD4+ T cells, as compared with mice immunized with EL
or CWSP (Fig. 6a). The increase in IL4+CD4+ T cell proportions
was higher only in ADS1 immunized mice, as compared to CWSP
immunized counterparts. These results indicate that immunization
with ADS, and more markedly with ADS1, induced a balanced
immune response encompassing pro- and anti-inflammatory
cytokine production.
Cytokine production was also assessed by ELISA in culture
supernatants of CWSP-stimulated splenocytes obtained from the
different used mouse groups, Before infection, a mild production
of pro-inflammatory cytokines IFN-c and IL-17 was detected in
CWSP-stimulated splenocytes of mice immunized with ADS1. That
was nevertheless higher than that detected in splenocytes of mice
immunized with CWSP or EL in which no or very little production
of these cytokines was detected (Fig. 7). At this time point, a mild
production of IFN-c was also detected in similarly stimulated
splenocytes of ADS2 immunized mice. In the cultures of spleno-
cytes collected at day 53 (3 days after C. albicans i.v. infection),
the levels of IFN-c were found significantly increased in culture
supernatants of all assessed splenocyte groups. However, produc-
tion of IL-17 and of IL-4 was markedly higher in the groups corre-
sponding to ADS1 immunized mice, detected in cultures of
splenocytes collected at days 52 and 56 (3 and 7 upon infection,
respectively). Splenocytes of the ADS2 immunized group also pro-
duced these cytokines upon stimulation, although at lower levels
than those detected in the ADS1 group. No IL-17 production was
detected in the remaining splenocyte culture from other mouse
groups. IL-4 production by splenocytes of the CWSP immunized
mice was detected, although at very low levels (Fig. 7). Interest-
ingly in the cultures of splenocytes collected from both ADS immu-
nized groups 3 and 7 days upon infection, significantly higher
levels of IL-10 were detected upon the antigenic stimulation than
in the other two groups (Fig. 7).
Fig. 3. BMDC activation by ADS. BMDC were incubated in vitro with medium alone (control) or stimulated with LPS, EL, CWSP, ADS1 or ADS2 as indicated, for 6 or 24 h. (a)
Flow cytometric analysis of CD80, CD86 and MHC class II molecule expression on the surface of BMDC. Bars represent mean fluorescence intensities (MFI) + SD due to
respective mAb staining of the indicated molecules. (b) Concentrations of the indicated cytokines detected in BMDC culture supernatants (bars represent mean + SD). Data
shown in (a) and (b) are pooled results from four independent experiments (n = 3 per group per experiment). BDL: below detection limit. Statistical significant differences are
represented above bars. Comparisons between control, LPS, EL, CWSP and ADS1 and the other groups are indicated by letters a, b, c, d and e, respectively (one, two, three and
four letters correspond to P < 0.05, P < 0.01, P < 0.001 and P < 0.0001, respectively).
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The surge of Candida species infections coupled to higher resis-
tance rates to antifungal drugs resulted in a tremendous increase
in the prevalence of systemic candidiasis in hospitalized patients
over the past two decades [30–33]. Hence, the development ofnovel immune-based approaches that could prevent Candida infec-
tions is of paramount interest.
In a previous study, we have shown that DODAB:MO liposomes
loaded with C. albicans CWSP improved the immunogenicity of
these antigens which suggested that these liposomes could be
promising delivery systems for use in vaccination against
Fig. 4. CWSP-specific IgG antibody titers and opsonophagocytic assay. (a) Specific anti-CWSP IgG1 and IgG2a were quantified in mice immunized s.c. with CWSP, ADS1, ADS2
or EL. Antibody titers were measured by ELISA using serum collected at day 49 (n = 4 per mouse group). The statistical significance between the different groups is indicated
above the lines: ⁄P < 0.05. (b) Serum obtained from four mice immunized with CWSP, ADS1, ADS2 or EL were used independently to opsonize yeast cells before interaction
with RAW264.7 cells. Three experimental replicates for each serum sample were performed. Phagocytosis was measured by flow cytometry after 30 min of incubation. Closed
bars correspond to the mean percentage + SD of macrophage cells with internalized (Sytox Green positive fluorescence) and open bars correspond to the mean percentage
+ SD of macrophage cells with only adhered yeast cells (PI + staining). Non-opsonized yeast cells are also represented (Control). (c) Representative confocal microscopy image
of internalized (Sytox Green+, *) and adhered (PI+, #) non-opsonized yeast cells by RAW264.7 macrophages. Statistical significant differences are represented above bars.
Comparisons between control, EL and CWSP and the other groups are indicated by letters a, b, and c, respectively (one, two, three and four letters correspond to P < 0.05,
P < 0.01, P < 0.001 and P < 0.0001, respectively).
Fig. 5. Protection conferred by ADS vaccination. Naive BALB/c mice were immunized s.c. with buffer (vehicle), EL, CWSP, ADS1 or ADS2, boosted twice, with an intervening
interval of 2 weeks, and infected intravenously (i.v.) with 1  105 C. albicans yeast-form cells, 21 days after the last s.c. immunization. Mice were sacrificed when reaching
humane endpoints and deaths were recorded in the following day. Groups that showed statistical significant differences on survival, and significance, were indicated in the
figure (n = 6 and n = 8 in control and immunized groups, respectively).
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good candidates for vaccine development due to their exposed
location [44]. In addition, the combination of antigens that are
related to key C. albicans virulence attributes or biological func-
tions may induce additive or synergistic immune responses and
therefore reduce the probability of fungal immune evasion [45].The ADS were prepared as two vaccine formulations, ADS1 and
ADS2, differing only in the total lipid concentration used for CWSP
adsorption. ADS1 is composed by approximately 7 times more
total lipid than ADS2 and, as a consequence, it retains 91 ± 12% of
the protein added, while ADS2 only retains 25 ± 12%, as previously
reported [26]. Its characterization confirmed the ADS mean sizes to
Fig. 6. a) Frequency of IFN-c+, IL-17+, IL-10+, or IL-4+ cells in splenic CD4+ T cells frommice s.c. immunized with CWSP, ADS1, ADS2 or liposomes, isolated 21 days after the last
s.c. immunization (before infection) and 3 and 7 days post-intravenous (i.v.) infection with 1  105 C. albicans yeast-form cells. Bars represent mean + SD of four mice used per
group. Statistical significant differences are represented above bars. Comparisons between EL, CWSP, ADS1 and the other groups are indicated by letters a, b, and c,
respectively (one, two and three letters correspond to P < 0.05, P < 0.01 and P < 0.001, respectively). (b) Representative examples of flow cytometry analysis of intracellular
IFN-c+, IL-17+, IL-10+, or IL-4+ expression on gated splenic CD4+ T cells before infection (day 0) or after 3 and 7 days of infection, as indicated, for mice immunized with CWSP
or ADS1. BDL: below detection limit. Numbers shown inside dot plots correspond to the frequency of cells as indicated.
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Fig. 7. Cytokine production by splenocytes stimulated with CWSP. Splenocytes from mice s.c. immunized with EL, CWSP, ADS1 or ADS2 were isolated 21 days after the last s.
c. immunization before infection (Day 0) and 3 and 7 days post-intravenous (i.v.) infection with 1  105 C. albicans yeast-form cells. Recall stimulation with CWSP (20 lg/ml)
was performed for 3 days and IFN- c, IL-17, IL-4 and IL-10 quantified by ELISA in the cell culture supernatants. Bars represent mean + SD (n = 4 per group). BDL: below
detection limit. Statistical significant differences are represented above bars. Comparisons between EL, CWSP, ADS1 and the other groups are indicated by letters a, b, and c,
respectively (one, two, three and four letters correspond to P < 0.05, P < 0.01, P < 0.001 and P < 0.0001, respectively).
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and that the antigenic proteins are adsorbed to the cationic lipo-
somes, as shown by f-potential values. Furthermore, the electro-
static interactions between the cationic liposomes and the
anionic proteins are strong enough to retain the antigens at the
ADS surface for at least 3 days after preparation. Importantly, the
quantity of antigens loaded in the ADS is dependent of the total
lipid concentration, but the stability of the core proteins at their
surface is not.
DC are important antigen presenting cells (APC) as they are very
effective in antigen capturing, processing and subsequent presen-
tation to antigen-specific T cells [41,46]. DC maturation in vitro is
characterized by up-regulation of MHC II and the co-stimulatory
molecules CD80 and CD86 [47]. Un-stimulated DC express moder-
ate levels of CD80, CD86 and MHC-II molecules on their surface.
Here we show that stimulation with ADS1, but not ADS2, signifi-
cantly elevated the expression of these three markers, in compar-
ison to cells exposed to the same concentration of free CWSP.
Importantly, the activation promoted by CWSP was more transient
than the one obtained with ADS1. This may indicate that delivery
of CWSP using the DODAB:MO liposomes resulted in more sus-
tained release of the target antigen or that the particulate nature
of the ADS1 improved the antigen uptake by DC. Accordingly, the
ability of cationic lipids to improve antigen immunogenicity was
also observed in previous reports [48–50]. In contrast to ADS1,
ADS2 was not effective in promoting significant DC activation.
The lower lipid concentration used in this system, which results
in just about 20% of CSWP entrapment, may explain the observed
lack of adjuvant effect and the response similar to the one of free
CWSP.
IL-12 and IL-23 are members of a family of heterodimeric pro-
inflammatory cytokines that can respectively promote Th1 andTh17 responses [51]. IL-12 induces IFN-c expression in CD4+ T cells
[52], and IL-23 maintains Th17 effector function [53]. In contrast,
IL-10 might be required to limit host damage under circumstances
of strong inflammation [54]. The cytokine profile obtained by stim-
ulating DC with ADS2 and free CWSP, encompassing TNF-a, IL-12
and IL-23 production, revealed a response similar to that elicited
by LPS, which could be considered as pro-inflammatory. On the
contrary, ADS1 seemed to be less inflammatory since these cytoki-
nes were present but in significantly reduced levels. In accordance
with a previous report [41], incubation of DC with EL didn’t lead to
production of significant levels of all cytokines, which indicates
that the marked pro-inflammatory response induced by CWSP
and ADS2 stimuli was likely due to the presence of high concentra-
tions of free proteins in the incubation solution. In accordance, C.
albicans cell wall proteins have been previously considered pro-
inflammatory [55,56].
Although ADS2 and CWSP induced a more marked pro-
inflammatory response by BMDC, ADS1 was the only system con-
ferring significant protection to C. albicans challenge. Cytokine pro-
duction analysis showed that mice immunized with ADS1
presented the highest frequency of splenic IL-17-producing CD4+
T cells. The bias towards IL-17 production in the ADS1 immunized
mice was confirmed by in vitro recall stimulation of splenocytes
with CWSP antigen. Contrastingly, no major differences among
groups were noticed in what concerned production of IFN-c. IL-
17 was shown to be a particularly important cytokine in mediating
protection against C. albicans infections in both humans and mice
[57]. Therefore, the detected higher production of IL-17 may have
contributed for the protective effect conferred by ADS1, as shown
by the extended survival of the mice immunized with this formu-
lation. IFN-c is also a recognized cytokine in mediating host pro-
tection against C. albicans [43]. However, as its production did
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assessed mouse groups it is unlikely that it may determine the
higher protective effect conferred by ADS1. ADS1 was the
antigen-delivery system inducing the highest production of
CWSP-specific antibodies, which led to, along with ADS2, to high-
est yeast opsonophagocytosis by macrophage cells. Immunization
with ADS1 resulted in higher protection, indicating that protection
could also be due to opsonizing antibodies raised by immunization
before infection. The host protective role of C. albicans cell-wall
specific antibodies has been previously documented [58] and
might be expected to also contribute for the immunoprotective
effect of the assessed ADS.
Although Th17 and Th1 cells, respective producers of IL-17 and
IFN- c, have been shown to be important in the development of
protective host responses against C. albicans infection [42,59], it
is the balance between pro- and anti-inflammatory signaling that
defines a successful fungal control [60,61]. In C. albicans infected
hosts Th1 cells secrete IFN-c favouring phagocyte cells activity
[43] while Th17 cells enhance neutrophil recruitment through
secretion of IL-17 [59,62]. Despite Th17 cells through IL-17 produc-
tion undoubtedly contribute to fungal elimination in infected
hosts, the pro-inflammatory effect of these cells may be deleterious
to the host [63]. Here, at day 3 post-infection, the pro-
inflammatory response was marked in all immunized mice. How-
ever, and importantly, also at this time point, the ADS immunized
mice showed the highest production of anti-inflammatory cyto-
kine IL-10. As previously remarked, a vaccine that could elicit by
itself an inflammatory reaction might end damaging the host when
the infectious agent is encountered. In such case, IL-10 production
may act as a homeostatic response to keep inflammation under
control [54,64]. Indeed, a previous reported experimental vaccine
that elicited a mixed response involving pro-inflammatory and
anti-inflammatory cytokines could provide host protection in the
absence of significant tissue pathology [65]. In mice immunized
with ADS1, the production of IFN-c and IL-17, Th1- and Th17-
type cytokines, respectively, as well as IL-4 and IL-10, Th2-type
and anti-inflammatory cytokines, respectively, supports the idea
that DODAB:MO liposomes contribute to a balanced immune
response against C. albicans infection, that ultimately culminated
in host extended survival, when compared with free CWSP immu-
nization. These results highlight once more the adjuvant potential
of these DODAB:MO liposomes, suggesting that a decrease in lipid
concentration could be fatal once ADS2 failed in inducing protec-
tion against systemic candidiasis.
Currently, scientific interest has grown towards the develop-
ment of nanoparticles for use as adjuvants and delivery of antigens
for vaccine development [66–70]. Other studies, using DODAB lipo-
somes with monophosphoryl lipid A (MPLA) or with trehalose 6,60-
dibehenate (TDB) as adjuvants, also resulted in a protective
immune response towards Chlamydia infection [71]. Similarly, in
another study, the combination of DODAB with a major antigen
of Paracoccidioides brasiliensis resulted in the lowest numbers of
viable yeast cells in mice infected with this fungus in comparison
with the use of other adjuvants such as aluminum hydroxide, Fre-
und’s Complete Adjuvant (CFA) or flagellin [72]. Other authors
have described enhanced protection provided by liposomes with
entrapped Candida antigens. In one of the studies the authors used
a double immunization strategy with priming antigen dose of
50 lg and boosted with 25 lg [61]. Chauhan and co-authors using
escheriosomes with entrapped Candida antigen were able to pro-
tect mice against C. albicans infection upon two immunizing
administrations using 100 lg of antigen per immunization [73].
Of note, in the present study only a total 30 lg of antigen were
used divided in three immunizing administrations, which is a
small amount in comparison to that used in other studies, support-
ing the high adjuvant potential of DODAB:MO liposomes. This wasthe first time that this novel DODAB:MO liposomal nanoparticle
associated with C. albicans CWSP was tested in a systemic C. albi-
cans infection reaching 62.5% protection. This reveals a good poten-
tial for future vaccine design. Nevertheless, the major goal of any
vaccine development is to achieve 100% protection. The adminis-
tration route is a key issue in vaccination by affecting the type
and strength of the elicited immune response [74]. Therefore the
intradermal and intramuscular routes may be worth to explore
in further studies as possible ways to achieve higher protection.5. Conclusion
This study demonstrated that DODAB:MO-based ADS efficiently
enhanced the stimulatory effect of CWSP and furthers the evidence
suggesting that it is a promising new vaccine antigen delivery sys-
tem. The in vivo results showed that by using DODAB:MO in the
ADS1 formulation, an immunizing dose as low as 10 lg of antigen
administered three times elicited significant humoral and cellular
immune responses in BALB/c mice, conferring significant protec-
tion against C. albicans systemic infection. Thus, the use of this
novel ADS1 liposomal nanoparticle revealed good potential for
future vaccine design.Disclosures
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